Insilico Medicine, a clinical stage end-to-end artificial intelligence (AI)-driven drug discovery company, today announces that leading AI analyst Margaretta Colangelo has joined the Company as Head of Communications, West and Middle East and North Africa (MENA). Colangelo, who has published over 400 articles and reports on AI in healthcare and has built a substantial following on LinkedIn, will guide Insilico’s public relations and communications strategy in the U.S., Canada, Europe, the Middle East, and North Africa.
Credit: Insilico Medicine
Insilico Medicine, a clinical stage end-to-end artificial intelligence (AI)-driven drug discovery company, today announces that leading AI analyst Margaretta Colangelo has joined the Company as Head of Communications, West and Middle East and North Africa (MENA). Colangelo, who has published over 400 articles and reports on AI in healthcare and has built a substantial following on LinkedIn, will guide Insilico’s public relations and communications strategy in the U.S., Canada, Europe, the Middle East, and North Africa.
Colangelo has been covering Insilico’s development since it was founded in 2014, and has amassed over 40,000 followers on LinkedIn and over 80,000 subscribers on her newsletters, which focus on the intersection of AI and healthcare. In addition to her communications expertise, Colangelo has extensive tech business experience, most recently as the cofounder of Jthereum, an enterprise software tools company that enables Java developers to develop enterprise applications for the Ethereum Blockchain. She was part of the team that developed the first Java-based secure messaging software for enterprise applications in the 1990s, technology that has been influential in advancing the industry.
“Margaretta has a deep and multifaceted understanding of business, science, and technology, and has built a dedicated following both on social media and throughout the industry,” says Insilico Medicine founder and CEO Alex Zhavorokov, PhD. “I’ve admired her contributions to the AI and healthcare space for many years, and I’m thrilled to have her help bring Insilico Medicine’s story to a larger audience.”
As an AI expert, Colangelo has chaired AI in healthcare tracks at conferences in the U.S., UK, Singapore, Switzerland, Italy, Germany, Brazil, Mexico, Saudi Arabia, Oman, Tanzania, and India. She’s also served as a guest lecturer at a number of universities, including King Abdulaziz University and University of Oxford Center for AI in Precision Medicines; University of Applied Sciences in Ansbach, Germany; Università Vita-Salute in San Raffaele, Italy; and Muhimbili University of Health and Allied Sciences in Tanzania.
Early in her career, Colangelo worked on the original technical support sales team at Nuance Communications, and she was the first person to sell JBoss open source Java application server consulting and training to Fortune 100 companies on Wall Street.
Colangelo served as President of U1 Technologies for 15 years providing mission critical, fault tolerant, ultra high performance communications infrastructure for stock trading platforms used by the world’s top multinational investment banks. She currently serves on the advisory board of the Artificial Intelligence Precision Health Institute at the University of Hawai’i Cancer Center, on the Board of Directors of Kitalys Institute in Washington DC., and on an expert committee for the International Financial Services Centres Authority in Gujarat International Financial Tec-City in India.
About Insilico Medicine
Insilico Medicine, a clinical stage end-to-end artificial intelligence (AI)-driven drug discovery company, is connecting biology, chemistry, and clinical trials analysis using next-generation AI systems. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques to discover novel targets and to design novel molecular structures with desired properties. Insilico Medicine is delivering breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system diseases and aging-related diseases. Headquartered in Hong Kong, Insilico Medicine has additional offices in New York, Montreal, Shanghai, Suzhou, Taipei, and Abu Dhabi. www.insilico.com
For media inquiries, please contact [email protected]